 Provider News New YorkFebruary 2024 Provider Newsletter Contents
NYBCBS-CDCRCM-048972-24 HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Please review your online provider directory information on a regular basis to ensure it is correct. Access your online provider directory information by visiting anthem.com, then at the top of the webpage, select Find Care. Submit updates and corrections to your directory information by following the instructions on the Provider Maintenance Form online. Update options include: - add/change an address location
- name change
- phone/fax number change
- provider leaving a group or a single location
- closing a practice location
The Consolidated Appropriations Act (CAA) implemented in 2021 contains a provision that requires online provider directory information be reviewed and updated as needed at least every 90 days. By reviewing your information regularly, you help us ensure your online provider directory information is current. We share a health vision with our care providers that means real change for consumers. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-049338-24 This article was published in error and retracted on February 21, 2024. Please access your state's updated version: Colorado, Connecticut, Georgia, Indiana, Kentucy, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin You may submit all your prior authorizations in one application on Availity.com.
You may already be submitting your prior authorizations through the Availity multi-payer Authorization application — taking advantage of the time savings and speed to care through digital authorization submissions. Beginning in March, you can submit both your physical health and behavioral health prior authorizations through one Authorization application on Availity.com.
You can still access the Interactive Care Reviewer (ICR) to review cases that were submitted through that application. You will also continue to use ICR to submit an appeal or authorization for medical specialty Rx.
Using the Availity Authorization application to submit your behavioral health prior authorizations will not be much different from the process you follow today. You may enjoy more intuitive screens or learn sooner if an authorization is required — but the digital submission process is still the very best way to submit your prior authorization and the fastest way to care for our members.
Training is available
If you aren’t already familiar with Availity Authorization, training is available. Select Availity Authorization Training to enroll for an upcoming live webcast or to access an on-demand recording.
Now, give it a try!
Accessing the Availity for authorization is easy. Ask your organization’s Availity administrator to ensure you have the Authorization role assignment. Without the role assignment, you will not be able to access the Authorization application. Then, log on to Availity.com to access the app through the Patient Registration tab by selecting Authorizations and Referrals.
Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-049149-23-CPN48082 Now accepting Medicaid and Medicare member claimsAs a care provider taking advantage of digital requests for additional information (Digital RFAI), you know it is the most efficient way to send the required documentation to process your Commercial member claims. As of February, you also can receive Digital RFAI notifications for your Medicaid and Medicare member claims. The process will not change for Medicaid and Medicare member claims. You will still follow the same fast and easy process for our Medicaid and Medicare member claims as you do for your commercial member claims. The only difference is that your Medicaid and Medicare member claims will not pend. Medicaid and Medicare member claims will deny when additional documentation is needed to process the claim.* Notifications will remain on your dashboard for up to 30 days for pended claims as they do today and 45 days for denied claims. After that, those notifications will move to the history tab of your dashboard.. Submit the documentation at your convenience (most care providers submit documents within seven to 14 days). Your notifications will continue to arrive on your dashboard each morning, making it convenient to plan your work; no need to check your dashboard throughout the day. * Claims for providers under pre-payment review will pend for 30 days. Learn more!In collaboration with Availity, we’ve developed training for your organization’s administrators about how to update the Medical Attachment registration.: Availity administrators can use this link to register for live training or to view the training on demand. For associates who are responsible for sending attachments, we’ve developed an enhanced training session that walks through the Attachments Dashboard and many of the unique features that make it most efficient. Availity users with the Medical Attachments and Claims Status role assignment can use this link to register for live training, or to view the live training on-demand. Contact Availity Customer Support at availity.com/Contact-Us or your provider relationship representative if you have any questions. Not a Digital RFAI care provider?If you’re not already using the Digital RFAI process and want to take advantage of faster claims processing, participation is easy. 1. | Registration | The organization’s Availity administrator will register for Medical Attachments, which enables care provider organizations to receive notices from the payer and submit requested documents digitally. | All billing NPIs/TINs must be registered. | 2. | User roles | The Availity administrator will be required to update or add new users with these specific role assignments through Availity: - Claims Status
- Medical Attachments
| Enable users to view the Availity Attachment Dashboard. | 3. | Ready to go! | After the registration and user roles are completed on Availity, the Digital RFAI process is ready. | Requests will automatically appear on the Attachments Dashboard each morning (when documents are needed). |
We are committed to finding solutions that help our care provider partners offer quality services to our members. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-049152-23-CPN48758 There may be times when a member requires a skilled home visit to assess their current status, instruct and reconcile medications, as well as instruct in early signs and symptoms of disease processes and complications to prevent hospitalization/re-hospitalization. Skilled nursing (SN) and therapies such as physical therapy (PT), occupational therapy (OT), or speech therapy (ST) at home may be a needed option post a hospital or inpatient rehab stay. These service providers would keep you, the primary care provider, apprised of the member’s status. We are working on two focus areas to assist members to get the care they need: - Postpartum members
- Members with a sepsis diagnosis
Postpartum membersThe State Department of Health has provided the guidance below regarding postpartum visits to Medicaid members as part of their benefit package. To attempt to improve New York State’s maternity morbidity and mortality rates, they provided the guidance below:1 - All postpartum persons are eligible for one initial postpartum home visit after they give birth.
- Pregnant/postpartum persons are also eligible for home visits in pregnancy and/or additional postpartum visits if determined to be medically necessary by the principal maternal care provider.
Members with a sepsis diagnosisStudies have shown that members with a sepsis diagnosis benefit from at least two post hospital home care skilled nursing visits: - A National Institutes of Health (NIH) funded study showed that timely home health nursing visits and outpatient follow-up within seven days after hospital discharge, significantly reduced readmissions.
- 7 percentage point reduction in sepsis (41% relative reduction)2.
We need your helpThe first step in this process starts with you, the provider. We will need signed orders for the home health agency in the community to provide these home visits. The process should begin while the member is still in the hospital as part of discharge planning. If the orders are not signed while the member is still in-patient, we will be reaching out to you to obtain the needed home health care orders. Together, we can work towards improved outcomes. Contact us- Call the prior authorization at 212-563-5570, ext. 1062001261, option 3.
Sources: 1 21.7 per 100,000 live birth Maternal mortality in NY The death rate of birthing people from complications of pregnancy or childbirth that occur during the pregnancy or within 6 weeks after the pregnancy ends. 2 National Center for Health Statistics, Mortality data, 2018-2021. National Center for Health Statistics, Natality data, 2022. Deb, P., Murtaugh, C., Bowles, K., Mikkelsen, M., Khajavi, H., Moore, S., Barron, Y., Feldman, P. (2019) Does Early Follow-Up Improve the Outcomes of Sepsis Survivors Discharged to Home Health Care? Medical Care, 57(8):633-640. PMID: 31295191. DOI: 10.1097/MLR.0000000000001152. Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-047041-23 On September 21, 2023, and October 4, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates Marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff. Please note:- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | March 1, 2024 | *CC-0248 | Elrexfio (elranatamab-bcmm) | New | March 1, 2024 | *CC-0249 | Talvey (talquetamab-tgvs) | New | March 1, 2024 | *CC-0250 | Veopoz (pozelimab-bbfg) | New | March 1, 2024 | *CC-0251 | Ycanth (cantharidin) | New | March 1, 2024 | *CC-0018 | Pompe Disease | Revised | March 1, 2024 | *CC-0021 | Fabrazyme (agalsidase beta) | Revised | March 1, 2024 | *CC-0046 | Zinplava (bezlotoxumab) | Revised | March 1, 2024 | CC-0182 | Iron Agents | Revised | March 1, 2024 | *CC-0068 | Growth Hormones | Revised | March 1, 2024 | CC-0156 | Reblozyl (luspatercept) | Revised | March 1, 2024 | *CC-0233 | Rebyota (fecal microbiota, live – jslm) | Revised | March 1, 2024 | *CC-0020 | Natalizumab Agents (Tysabri, Tyruko) | Revised | March 1, 2024 | CC-0064 | Interleukin-1 Inhibitors | Revised | March 1, 2024 | CC-0026 | Testosterone Injectable | Revised |
Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-048719-23-CPN48226 SummaryOn September 21, 2023, and October 4, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | February 19, 2024 | *CC-0248 | Elrexfio (elranatamab-bcmm) | New | February 19, 2024 | *CC-0249 | Talvey (talquetamab-tgvs) | New | February 19, 2024 | *CC-0250 | Veopoz (pozelimab-bbfg) | New | February 19, 2024 | *CC-0251 | Pompe Disease | New | February 19, 2024 | *CC-0018 | Pompe Disease | Revised | February 19, 2024 | *CC-0021 | Fabrazyme (agalsidase beta) | Revised | February 19, 2024 | *CC-0046 | Zinplava (bezlotoxumab) | Revised | February 19, 2024 | CC-0182 | Iron Agents | Revised | February 19, 2024 | *CC-0068 | Growth Hormones | Revised | February 19, 2024 | CC-0156 | Reblozyl (luspatercept) | Revised | February 19, 2024 | *CC-0233 | Rebyota (fecal microbiota, live – jslm) | Revised | February 19, 2024 | *CC-0020 | Natalizumab Agents (Tysabri, Tyruko) | Revised | February 19, 2024 | CC-0064 | Interleukin-1 Inhibitors | Revised | February 19, 2024 | CC-0026 | Testosterone Injectable | Revised | February 19, 2024 | *CC-0247 | Beyfortus (nirsevimab) | Revised |
Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CR-047343-23-CPN47070 Effective June 1, 2024, Anthem will transition from CG-BEH-02 (Adaptive Behavioral Treatment) and MCG W0153 (Behavioral Health Care Applied Behavioral Analysis), to MCG B-806-T Behavioral Health Care Applied Behavioral Analysis (Original MCG Guideline), for medical necessity/clinical appropriateness reviews. If you have questions, please contact the provider service number on the back of the member's ID card. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-047274-23 BackgroundIn February 2022, updates to Clinical Utilization Management (UM) Guidelines were published with an August 1, 2022, effective date. These updates included changes to clinical coding edits for the lab test indicated below. UpdateThe updated guidelines state that only medically necessary lab testing will be covered. Effective March 1, 2024, coverage for these labs will be denied unless medically necessary: Clinical UM Guideline number/title | Clinical indications for medical necessity | MCD ENT — CG-Lab-29: Gamma Glutamyl Transferase Testing | GGT testing using blood is considered medically necessary for any of the following indications: - To differentiate between sources of elevated alkaline phosphatase activity; or
- To evaluate liver function, injury, or disease in individuals with at least one of the following:
- Known or suspected hepatobiliary disease; or
- Alcohol use disorder; or
- Substance use disorder; or
- Therapy with medication that has potentially toxic effects on the liver; or
- Exposure to hepatotoxins; or
- Infections that may cause liver injury (for example, viral hepatitis, amoebiasis, tuberculosis, and similar infections); or
- Pancreatic disease; or
- Gastrointestinal disease; or
- Liver transplantation; or
- Primary or secondary malignant neoplasms; or
- Diseases or conditions known to have liver involvement (for example, diabetes mellitus, sarcoidosis, amyloidosis, disorders of iron and mineral metabolism, lupus, hypertension, heart failure).
|
Clinical UM Guideline number/title | Clinical indications for medical necessity | MCD ENT-CG — Lab-30: Outpatient Laboratory-based Blood Glucose Testing | Blood glucose testing is considered medically necessary for individuals who meet any of the following criteria (A through Q): - Signs or symptoms of either of the following:
- Hypoglycemia; or
- Hyperglycemia; or
- Overweight or obesity* of any age; or
- From a population with a high prevalence of diabetes mellitus**; or
- Impaired fasting glucose has been found on other testing; or
- Pregnant and considered to be at high risk for type 2 diabetes mellitus; or
- Prior testing at least 3 months previously showed abnormal blood glucose results; or
- Insulin resistance syndrome; or
- Carbohydrate intolerance; or
- Hypoglycemia disorders, such as nesidioblastosis or insulinoma; or
- Catabolic or malnutrition states; or
- Tuberculosis; or
- Unexplained chronic or recurrent infection; or
- Alcohol use disorder; or
- Coronary artery disease; or
- Unexplained skin conditions (including pruritis, local skin infections, ulceration, and gangrene without an established cause); or
- Chronic glucocorticoid therapy; or
- To evaluate glycemic status for individuals with established diabetes mellitus, prediabetes, or a history of gestational diabetes when done no more often than the following test frequencies:
- Up to once yearly for individuals with prediabetes; or
- Up to two times per year for individuals with diabetes mellitus who are meeting treatment goals; or
- Within the first year postpartum and then up to once yearly for individuals who have had gestational diabetes.
Notes: * ADA, ACOG, and USPSTF recommendations about individuals who have overweight or obesity and ** Populations with high prevalence of diabetes mellitus |
What if I have questions?Availity Chat with Payer is available during normal business hours. Get answers to your questions about eligibility, benefits, authorizations, claims status, and more. To access Availity Essentials, go to Availity.com and select the appropriate payer space tile from the drop-down. Then, select Chat with Payer and complete the pre-chat form to start your chat. For additional support, visit the Contact Us section at the bottom of our provider's website for the appropriate contact. Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-047587-23-CPN47422 These updates list the new and/or revised Medical Policies and Clinical Guidelines for Anthem. The implementation date for each policy or guideline is noted for each section. Implementation of the new or revised Medical Policy or Clinical Guideline is effective for all claims processed on and after the specified implementation date, regardless of date of service. Previously processed claims will not be reprocessed as a result of the changes. If there is any inconsistency or conflict between the brief description provided below and the actual policy or guideline, the policy or guideline will govern. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and Clinical Guidelines (and Medical Policy takes precedence over Clinical Guidelines) and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that the service is rendered must be used. This document supplements any previous Medical Policy and Clinical Guideline updates that may have been issued by Anthem. Please include this update with your provider manual for future reference. Please note that Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Anthem’s Medical Policies and Clinical Guidelines are available at anthem.com. Select For Providers. Under the Provider Resources heading, select Policies, Guidelines & Manuals. Select your state. Then, select View Medical Policies & Clinical UM Guidelines. Note: These updates may not apply to all administrative services only accounts as some accounts may have nonstandard benefits that apply. To view Medical Policies and Clinical Utilization Management (UM) Guidelines applicable to members enrolled in the Blue Cross and Blue Shield Service Benefit Plan (commonly referred to as the Federal Employee Program [FEP®]), visit fepblue.org > Policies & Guidelines. Medical Policy updatesNew Medical Policy effective May 11, 2024 The following policy is new: - RAD.00068 Myocardial Strain Imaging
Revised Medical Policies effective May 11, 2024 The policies below were revised and might result in services that were previously covered but may now be found to be either not medically necessary and/or investigational: - MED.00120 Gene Therapy for Ocular Conditions
- SURG.00026 Deep Brain, Cortical, and Cerebellar Stimulation
- SURG.00097 Scoliosis Surgery
- SURG.00142 Genicular Procedures for Knee Pain
Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CM-048578-23 Effective for dates of service on and after May 1, 2024, the following codes will require prior authorization through Carelon Medical Benefits Management, Inc. CPT® code | Description | 0239U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations | 0306U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations | 0307U | Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for | 0356U | Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement | 0368U | Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer | 0326U | Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden |
As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management in one of several ways: - Access the ProviderPortalSM directly at providerportal.com:
- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
- Access via Availity.com.
If you have questions related to guidelines, please contact Carelon via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here. With your help, we can continually build towards a future of shared success. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-048270-23-CPN48141 As part of our ongoing quality improvement efforts, we will be implementing a new Genetic Testing (GT) claim to authorization match enhancement that will ensure GT panels billed have a corresponding authorization. This enhanced match logic will be effective by May 1, 2024. Labs that bill panels with codes in excess of what has been authorized may receive a full claim denial. The goal of this enhanced match logic is to ensure tests performed are authorized and meet medical necessity requirements. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc., licensees of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. NYBCBS-CM-047629-23-CPN47301 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. UPDATE: This article was originally published as being effective March 1, 2024. The effective date has been delayed to May 1, 2024. Effective May 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicare members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | 0738T | Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination | 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and int |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on https://providers.anthem.com/ny or for contracted providers by accessing Availity.com. Providers may also call the number on the back of their patient’s member ID card for Provider Services for assistance with PA requirements. UM AROW #: A2023M0443 Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CR-044240-23-CPN43832, CPN-CRMMP-049296-24, NYBCBS-CR-044241-23-CPN43832 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. UPDATE: This article was originally published as being effective March 1, 2024. The effective date has been delayed to May 1, 2024. Effective May 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicare members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | Q4272 | Esano a, per square centimeter | Q4273 | Esano aaa, per square centimeter | Q4274 | Esano ac, per square centimeter | Q4275 | Esano aca, per square centimeter | Q4276 | Orion, per square centimeter | Q4277 | Woundplus membrane or e-graft, per square centimeter | Q4278 | Epieffect, per square centimeter | Q4280 | Xcell amnio matrix, per square centimeter | Q4281 | Barrera sl or barrera dl, per square centimeter | Q4282 | Cygnus dual, per square centimeter | Q4283 | Biovance tri-layer or biovance 3l, per square centimeter | Q4284 | Dermabind sl, per square centimeter |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on https://providers.anthem.com/ny or for contracted providers by accessing Availity.com. Providers may also call the number on the back of their patient’s member ID card for Provider Services for assistance with PA requirements. UM AROW #: A2023M0417 Medicare services provided by Anthem Blue Cross, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CR-044202-23-CPN43849, CPN-CRMMP-049296-24, NYBCBS-CR-044203-23-CPN43849 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. UPDATE: This article was originally published as being effective March 1, 2024. The effective date has been delayed to May 1, 2024. Effective May 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA for by Anthem for Medicare members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | E0761 | Non-Thermal Pulsed High Frequency Radiowaves, High Peak Power Electrom |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on https://providers.anthem.com/ny on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call the number on the back of their patient’s member ID card for Provider Services. UM AROW #: A2023M0415 Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CR-044188-23-CPN43845, CPN-CRMMP-049296-24, NYBCBS-CR-044189-23-CPN43845 Beginning with dates of service on or after May 1, 2024, Anthem will implement a new reimbursement policy titled Modifier Usage — Facility based on the code-set combinations submitted with the correct modifiers. This reimbursement policy identifies the following three different types of facility modifiers: - Reimbursement modifiers affect payment and denote circumstances when an increase or reduction is appropriate for the service provided.
- Informational modifiers impacting reimbursement determine if the service provided will be reimbursed or denied.
- Informational modifiers not impacting reimbursement are used for documentation purposes.
The Related Coding section of the policy includes a Facility Modifier code list which identifies the modifier, the modifier description, and any related reimbursement policies. The Facility Modifier code list also includes six modifiers that do not have associated reimbursement policies. These modifiers indicate a reduced service or different equipment was used for the service. These modifiers will result in a reduction when billed on a facility claim. For specific policy details, visit the reimbursement policy page at anthem.com. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-047155-23-SRS47155 Beginning with dates of service on or after April 1, 2024, Anthem will not reimburse for the following when billed on a UB-04: - Consultation CPT® codes 99242–99245, 99251–99255
- Prolonged Services codes 99354–99359, 99415–99417 and G2212
For appropriate billing guidelines of Consultation and Prolonged Services CPT codes, please refer to the corresponding professional Reimbursement Policies: - Prolonged Services
- Consultation Services
For specific policy details, visit the reimbursement policy page at anthem.com. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-047188-23 Call to actionWe need to rethink and refocus the way we care for people living with sickle cell disease (SCD). Anthem has created a comprehensive SCD care management program. The program partners with members and care providers to remove barriers to care, improve and facilitate treatment adherence, and increase the quality of life for people living with SCD. By focusing on the prevention of SCD complications and building strategies for effective pain management, we aim to reduce preventable emergency department (ED) utilization and hospital admissions. Our goal is to ensure that members with SCD are receiving comprehensive whole person care that goes beyond treating SCD symptoms. We will provide disease education, medication adherence monitoring, care coordination, as well as connect members to community resources. By building trusting relationships between Anthem, members, care providers, and community resources, we empower our members to achieve the best quality of life possible. To refer a Medicaid-enrolled member to the SCD Care Coordination program, call Provider Services at 800-450-8753. Why this is importantSCD is a chronic condition and is the most common inherited red blood cell disorder in the United States affecting at least 100,000 Americans1. The Center for Disease Control and Prevention (CDC) reports that SCD affects one out of every 365 Black and African American births and one out of every 16,300 Hispanic and Latin X births1. Most care providers are familiar with the unpredictable symptoms and long-term morbidities that individuals affected by SCD experience, including pain and vaso-occlusive crises, depression, and fatigue. Repeated vaso-occlusion, infarction, and chronic hemolytic anemia lead to organ dysfunction. More than half of people living with SCD have some organ disease and at least 24 percent have damage affecting multiple organs2. Vaso-occlusive events can have devastating consequences across all age groups. For example, it is estimated that 50 percent of people with SCD will experience cerebral vasculopathy by age 14 and 25 percent of adults with SCD will experience a stroke by age 45.2 Care providers might lose sight of the high medical costs (estimated to be over $1 million per individual lifetime6,1), barriers to care, and reduced quality of life people with SCD face. Despite medical advances in treatments such as medications and gene therapy, large discrepancies in both outcomes and mortality rates for people with SCD still remain. One startling national statistic shows that life expectancy for people with SCD is at least 22 years lower than that for people without SCD6. These gaps can be attributed to multiple factors including limited access to comprehensive care. The effects of SCD on quality of life are often unrecognized. Patients with SCD are more likely than people without SCD to have lost workdays and missed school days because of time spent in the hospital or ED6. The prevalence of depression and anxiety among people with SCD is five times greater than that of the general population.2 Patient experience is linked to their perceptions of quality of care.10 Many people living with SCD report dissatisfaction with the quality of care they receive. Contributing factors to this dissatisfaction include perceptions of racial discrimination, feelings of being stereotyped as drug seekers who do not have legitimate pain, barriers to accessing specialty care, and lack of clinician comfort with disease management – especially pain.10 The presence of implicit racial bias in healthcare and perceptions of discrimination are directly linked to negative health experiences.2 One example comes from a published study that showed people with sickle cell crisis in the ED waited 50 percent longer for pain treatment than patients who arrived with long bone fractures.3 In another study of ED wait times, patients with SCD waited an average of two hours longer for initial pain treatment compared to patients without SCD.3 Negative healthcare experiences lead to feelings of mistrust, which result in poor health outcomes. Patients with SCD who report experiences of discrimination are 53 percent more likely to report nonadherence to physician treatment recommendations.10 The lack of trusting relationships with healthcare providers correlates to low patient self-efficacy. This is compounded by obstacles related to social determinants of health which disproportionately affect many individuals living with SCD. Many primary care providers (PCPs) have few, if any, patients with SCD in their practices. Surveys show that care providers are often uncomfortable with SCD management especially when it comes to pain treatment. People living with SCD will benefit from closer partnerships with their PCPs. References
- American Society of Hematology. (2022). The cost of living with sickle cell disease. https://tinyurl.com/2ezzzwzt.
- BlueBirdBio. (n.d.). We can change SCD. changeforscd.com/
- Hutchinson S. (2023). For people with sickle cell disease, ERs can mean life-threatening waits. https://tinyurl.com/2fy2n5mb
- Jang T, Poplawska M, et al. (2021). Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. Journal of Translational Medicine. 10.1186/s12967-021-03074-z
- Johnson KM, Boshen J, et al. (2023). Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Advances, 7(3). http://tinyurl.com/2phs7hcy
- Lubeck D, Agodoa I, Bhakta N, et al. (2019) Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Network Open. http://tinyurl.com/5n8wyfrw
- Mainous AG, Tanner RJ, et al. (2015) Attitudes toward management of sickle cell disease and its complications: A national survey of academic family physicians. Anemia. Article ID 853835. http://tinyurl.com/2s5nwax9
- National Institutes of Health. (2022). Researchers identify the high costs of living with sickle cell disease. https://tinyurl.com/3mw6spxc
- Onimoe G, Rotz S. (2020) Sickle cell disease: a primary care update. 87(1) 19-27 ccjm.org/content/87/1/19
- Oyedeji C, Strouse J. Improving the quality of care for adolescents and adults with sickle cell disease – it’s a long road. JAMA Network Open. 2020;3(5) http://tinyurl.com/4464y44y
- United States, Department of Health and Human Services, Centers for Disease Control and Prevention. (7 July 2023). Are family physicians comfortable treating people with sickle cell disease? Centers for Disease Control and Prevention. https://tinyurl.com/yhr4tyb7
- Wachnik, AA, Welch-Coltrane, JL, Adams, MC, et al. (2022) A standardized emergency department order set decreases admission rates and in-patient length of stay for adult patients with sickle cell disease. Pain Medicine. https://doi.org/10.1093/pm/pnac096
Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-045506-23-CPN44338 The Anthem pre-service clinical review of non-oncology specialty pharmacy drugs will be managed by the Medical Specialty Drug Review team of Anthem. Oncology drugs will be managed by Carelon Medical Benefits Management, Inc., a separate company. The following Clinical Criteria documents were endorsed at the November 17, 2023, Clinical Criteria meeting. To access the Clinical Criteria information, visit this link. New Clinical Criteria effective May 1, 2024The following Clinical Criteria are new: - CC-0253 Aphexda (motixafortide)
- CC-0254 Zilbysq (zilucoplan)
Revised Clinical Criteria effective May 1, 2024The following Clinical Criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary: - CC-0002 Colony Stimulating Factor Agents
- CC-0009 Lemtrada (alemtuzumab) for the Treatment of Multiple Sclerosis
- CC-0011 Ocrevus (ocrelizumab)
- CC-0014 Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis
- CC-0020 Natalizumab Agents (Tysabri, Tyruko)
- CC-0032 Botulinum Toxin
- CC-0041 Complement Inhibitors
- CC-0042 Monoclonal Antibodies to Interleukin-17
- CC-0050 Monoclonal Antibodies to Interleukin-23
- CC-0062 Tumor Necrosis Factor Antagonists
- CC-0063 Ustekinumab Agents (Stelara, Wezlana)
- CC-0064 Interleukin-1 Inhibitors
- CC-0065 Agents for Hemophilia A and von Willebrand Disease
- CC-0066 Monoclonal Antibodies to Interleukin-6
- CC-0068 Growth Hormone
- CC-0071 Entyvio (vedolizumab)
- CC-0078 Orencia (abatacept)
- CC-0086 Spravato (esketamine) Nasal Spray
- CC-0170 Uplizna (inebilizumab-cdon)
- CC-0173 Enspryng (satralizumab-mwge)
- CC-0174 Kesimpta (ofatumumab)
- CC-0182 Iron Agents
- CC-0199 Empaveli (pegcetacoplan)
- CC-0226 Elahere (mirvetuximab)
Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CM-048604-23 This article was updated on July 23, 2024 to correct the Clinical Criteria for Spravato (esketamine) from CC-0066 to CC-0086. Specialty pharmacy updates for Anthem are listed belowPrior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s Medical Specialty Drug Review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc., a separate company. Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications. Inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code. Prior authorization updatesUpdate: In the May 2023 edition of Provider News, we announced prior authorization for Adstiladrin will be effective August 2023. Review of Adstiladrin is managed by Carelon Medical Benefits Management. Effective for dates of service on and after May 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our prior authorization review process. Access our Clinical Criteria to view the complete information for these prior authorization updates. Clinical Criteria | Drug | HCPCS or CPT® code(s) | CC-0252 | Adzynma (ADAMTS13, recombinant-krhn) | C9399 | CC-0253* | Aphexda (motixafortide) | J3490, J3590, J9999 | CC-0042 | Bimzelx (bimekizumab-bkzx) | J3490 | CC-0032 | Daxxify (daxibotulinumtoxinA-lanm) | C9160 | CC-0050 | Omvoh (mirikizumab-mrkz) | J3590 | CC-0066* | Tofidence (tocilizumab-bavi) | J3490, J3590 | CC-0254 | Zilbysq (zilucoplan) | J3490 | CC-0062 | Zymfentra (infliximab-dyyb) | J3590 |
* Oncology use is managed by Carelon Medical Benefits Management. Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. Quantity limit updatesEffective for dates of service on and after May 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our quantity limit review process. Access our Clinical Criteria to view the complete information for these quantity limit updates. Clinical Criteria | Drug | HCPCS or CPT code(s) | CC-0042 | Bimzelx (bimekizumab-bkzx) | J3490 | CC-0032 | Daxxify (daxibotulinumtoxinA-lanm) | C9160 | CC-0050 | Omvoh (mirikizumab-mrkz) | J3590 | CC-0066 | Tofidence (tocilizumab-bavi) | J3490, J3590 | CC-0254 | Zilbysq (zilucoplan) | J3490 | CC-0062 | Zymfentra (infliximab-dyyb) | J3590 | CC-0086 | Spravato (esketamine) | G2082, G2083, S0013 |
Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-048938-24-CPN48884 This article was published in error and retracted on February 23, 2024. Please access your state's updated version: Colorado, Connecticut, Georgia, Indiana, Kentucy, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin Effective for dates of service on and after May 1, 2024, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process.
Federal and state law, as well as state contract language and CMS guidelines (including definitions and specific contract provisions/exclusions), take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.
HCPCS or CPT® codes
| Medicare Part B drugs
| J3490, J3590, J9999, C9399
| Elrexfio (elranatamab-bcmm)
| J3490, J3590
| Eylea HD (aflibercept)
| J3490, J3590
| Pombiliti (cipaglucosidase alfa-atga)
| J3490, J3590, J9999, C9399
| Talvey (talquetamab-tgvs)
| J3490, J3590
| Tyruko (natalizumab-sztn)
| J3590, C9399
| Veopoz (pozelimab-bbfg)
| J3490
| Ycanth (cantharidin)
|
Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-046706-23-CPN45768 The formulary changes listed in the table were reviewed and approved at our third quarter 2023 Pharmacy and Therapeutics Committee meeting. Effective February 1, 2024, the changes outlined apply to all Anthem members. Please remember to read the footnotes at the end of the table. Refer to attachment to view full drug details Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-048223-23 ATTACHMENTS (available on web): Quarterly pharmacy formulary change notice (pdf - 1.15mb) Hispanics are the largest ethnic minority group in the United States, making it vital that we recognize the unique health needs of the population. Take time in February to support American Heart Health Month and explore how your practice can help improve your Hispanic patients’ heart health. What can your practice do to help improve health outcomes for Hispanic patients with heart disease?- Be proactive about asking if the patient requires interpretation services. No one wants to feel like a burden. By asking and preparing for an interpreter in advance, you are creating a welcoming atmosphere for the patient during their appointment. If you would like to request an interpreter, including sign language, on behalf of your Anthem patients, call Provider Services. Free interpreter services are also available to members by calling the Member's Services number on the back of their ID card (TTY/TTD 711) and through the 24/7 NurseLine.
- According to a study by the American Heart Association (link), Hispanic persons had similar rates of heart disease compared to Caucasian adults but lower rates of awareness and control. To help increase awareness of their condition, you can ask questions such as:
- “Have you ever been told that you have high blood pressure or high cholesterol?”
- “Has a healthcare provider ever discussed with you or prescribed you medication to control your blood pressure or cholesterol levels?”
- Once awareness of the condition is properly understood, educate the patient on any increased health risk factors they might have, especially if they have other conditions like diabetes or obesity.
- Use culturally appropriate examples when discussing lifestyle changes.
- Encourage scheduling follow-up appointments for blood pressure rechecks or lab work to check cholesterol levels before the patient leaves the office.
- Submit all blood pressure readings using Category II codes on claims or through your practice’s preferred supplemental data submission method. Blood pressure care gaps can open and close through the year and are based on the last recorded blood pressure reading of the year. The goal for every patient is a reading below 140/90 mmHg.
- Properly code statin therapy exclusions and prescribe low-cost medications to discourage the use of discount cards.
To learn more about our commitment to health equity, visit MyDiversePatients.com. Your patients can also learn more about the unique health needs of Hispanic persons by visiting takingactionforourhealth.org/. Patient care opportunitiesIf you have questions on improving your quality scores, contact your care consultant or program manager to discuss your opportunities. You also can find patient care opportunities within the Patient360 application located on Availity Essentials Payer Spaces. To access the Patient360 application you must have the Patient360 role assignment. From Availity’s home page, select Payer Spaces, then choose the health plan from the menu. Choose the Patient360 tile from the Payer Space Applications menu and complete the required information on the screen. Gaps in care are in the Active Alerts section of the Member Summary. What if I need assistance?If you have questions about this communication or need assistance with any other item, contact your local provider relationship management associate or call Provider Services at 800-300-8181. Through our efforts, we can help deliver high quality, equitable healthcare. NYBCBS-CD-040694-23-CPN39313 Hispanics are the largest ethnic minority group in the United States, making it vital that we recognize the unique health needs of the population. Take time in February to support American Heart Health Month and explore how your practice can help improve your Hispanic patients’ heart health. What can your practice do to help improve health outcomes for Hispanic patients with heart disease?- Be proactive about asking if the patient requires interpretation services. No one wants to feel like a burden. By asking and preparing for an interpreter in advance, you are creating a welcoming atmosphere for the patient during their appointment. If you would like to request an interpreter, including sign language, on behalf of your Anthem patients, call Provider Services. Free interpreter services are also available to members by calling the Member's Services number on the back of their ID card (TTY/TTD 711) and through the 24/7 NurseLine.
- According to a study by the American Heart Association (link), Hispanic persons had similar rates of heart disease compared to Caucasian adults but lower rates of awareness and control. To help increase awareness of their condition, you can ask questions such as:
- “Have you ever been told that you have high blood pressure or high cholesterol?”
- “Has a healthcare provider ever discussed with you or prescribed you medication to control your blood pressure or cholesterol levels?”
- Once awareness of the condition is properly understood, educate the patient on any increased health risk factors they might have, especially if they have other conditions like diabetes or obesity.
- Use culturally appropriate examples when discussing lifestyle changes. Select here for our conversation guide for tips on how to engage patients who may be from a culture different from your own.
- Encourage scheduling follow-up appointments for blood pressure rechecks or lab work to check cholesterol levels before the patient leaves the office.
- Submit all blood pressure readings using Category II codes on claims or through your practice’s preferred supplemental data submission method. Blood pressure care gaps can open and close through the year and are based on the last recorded blood pressure reading of the year. The goal for every patient is a reading below 140/90 mmHg.
- Properly code statin therapy exclusions and prescribe low-cost medications to discourage the use of discount cards.
To learn more about our commitment to health equity, visit MyDiversePatients.com. Your patients can also learn more about the unique health needs of Hispanic persons by visiting takingactionforourhealth.org/. Patient care opportunitiesIf you have questions on improving your quality scores, contact your care consultant or program manager to discuss your opportunities. You also can find patient care opportunities within the Patient360 application located on Availity Essentials Payer Spaces. To access the Patient360 application you must have the Patient360 role assignment. From Availity’s home page, select Payer Spaces, then choose the health plan from the menu. Choose the Patient360 tile from the Payer Space Applications menu and complete the required information on the screen. Gaps in care are in the Active Alerts section of the Member Summary. What if I need assistance?If you have questions about this communication or need assistance with any other item, contact your local provider relationship management associate or call Provider Services on the back of your patient’s member ID card. Through our efforts, we can help deliver high quality, equitable healthcare. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CM-040696-23-CPN39313 Hispanics are the largest ethnic minority group in the United States, making it vital that we recognize the unique health needs of the population. Take time in February to support American Heart Health Month and explore how your practice can help improve your Hispanic patients’ heart health. What can your practice do to help improve health outcomes for Hispanic patients with heart disease?- Be proactive about asking if the patient requires interpretation services. No one wants to feel like a burden. By asking and preparing for an interpreter in advance, you are creating a welcoming atmosphere for the patient during their appointment. If you would like to request an interpreter, including sign language, on behalf of your Empire BlueCross BlueShield patients, call Provider Services. Free interpreter services are also available to members by calling the Member's Services number on the back of their ID card (TTY/TTD 711) and through the 24/7 NurseLine.
- According to a study by the American Heart Association (link), Hispanic persons had similar rates of heart disease compared to Caucasian adults but lower rates of awareness and control. To help increase awareness of their condition, you can ask questions such as:
- “Have you ever been told that you have high blood pressure or high cholesterol?”
- “Has a healthcare provider ever discussed with you or prescribed you medication to control your blood pressure or cholesterol levels?”
- Once awareness of the condition is properly understood, educate the patient on any increased health risk factors they might have, especially if they have other conditions like diabetes or obesity.
- Use culturally appropriate examples when discussing lifestyle changes. Select here for our conversation guide for tips on how to engage patients who may be from a culture different from your own.
- Encourage scheduling follow-up appointments for blood pressure rechecks or lab work to check cholesterol levels before the patient leaves the office.
- Submit all blood pressure readings using Category II codes on claims or through your practice’s preferred supplemental data submission method. Blood pressure care gaps can open and close through the year and are based on the last recorded blood pressure reading of the year. The goal for every patient is a reading below 140/90 mmHg.
- Properly code statin therapy exclusions and prescribe low-cost medications to discourage the use of discount cards.
To learn more about our commitment to health equity, visit MyDiversePatients.com. Your patients can also learn more about the unique health needs of Hispanic persons by visiting takingactionforourhealth.org/. Patient care opportunitiesIf you have questions on improving your quality scores, contact your care consultant or program manager to discuss your opportunities. You also can find patient care opportunities within the Patient360 application located on Availity Essentials Payer Spaces. To access the Patient360 application you must have the Patient360 role assignment. From Availity’s home page, select Payer Spaces, then choose the health plan from the menu. Choose the Patient360 tile from the Payer Space Applications menu and complete the required information on the screen. Gaps in care are in the Active Alerts section of the Member Summary. What if I need assistance?If you have questions about this communication or need assistance with any other item, contact your local provider relationship management associate or call Provider Services on the back of your patient’s member ID card. Through our efforts, we can help deliver high quality, equitable healthcare. Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CR-040695-23-CPN39313 HEDIS® 2023 documentation for Blood Pressure Control for Patients With Diabetes (BPD) Measure description
The percentage of members 18 to 75 years of age with diabetes (types 1 and 2) whose blood pressure (BP) was adequately controlled (< 140/90 mm Hg) during the measurement year. What we are looking for in provider records:- Last BP documented in 2023 regardless of reading
- Evidence of hospice or palliative services in 2023
- Evidence patient expired in 2023
- Documentation of polycystic ovarian syndrome, gestational diabetes, or steroid induced diabetes
Helpful hints:- Take a second BP at the end of the office visit if initial BP was > 140/90.
- Consider taking BP at every visit.
- Counsel on healthy habits for managing high blood pressure.
- Encourage medication adherence.
- Member-reported BPs during a telehealth visit are acceptable.
- Review diabetic services needed at each office visit.
- For members who have not been diagnosed with diabetes but take a diabetes medication for off-label use, document why they are taking medication (for example, weight loss, congestive heart failure, chronic kidney disease, etc.).
HEDIS 2023 documentation for Hemoglobin A1c Control for Patients With Diabetes (HBD) Measure descriptionThe percentage of members 18 to 75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year: - HbA1c control (< 8.0%)
- HbA1c poor control (> 9.0%)
What we are looking for in provider records:- Last HbA1c documented in 2023 regardless of result
- Evidence of hospice or palliative services in 2023
- Evidence patient expired in 2023
- Documentation of polycystic ovarian syndrome, gestational diabetes, or steroid induced diabetes
Helpful hints:- Counsel on healthy habits for managing diabetes.
- If appropriate, set an HbA1c goal of less than 7%.
- Encourage timely HbA1c testing.
- Encourage medication adherence.
- Encourage continuous glucose monitoring.
- In progress notes when documenting HbA1c value include date the test was performed.
- Review diabetic services needed at each office visit.
- For members who have not been diagnosed with diabetes but take a diabetes medication for off-label use, document why they are taking medication (for example, weight loss, congestive heart failure, chronic kidney disease, etc.).
HEDIS 2023 documentation for Eye Exam for Patients With Diabetes (EED) Measure descriptionThe percentage of members 18 to 75 years of age with diabetes (types 1 and 2) who had a retinal eye exam. What we are looking for in provider records:- Evidence of a retinal eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year or year prior with results
- Bilateral eye enucleation any time during the member’s history
- Evidence of hospice or palliative services in 2023
- Evidence patient expired in 2023
- Documentation of polycystic ovarian syndrome, gestational diabetes, or steroid induced diabetes
Helpful hints:- Refer patients to an optometrist or ophthalmologist for a dilated or retinal eye exam annually.
- Fundus/retinal photography is considered imaging and is eligible for use; must be dated and interpreted by an eye care professional.
- Counsel on healthy habits for managing diabetes.
- In progress notes when documenting a retinal eye exam include the name of eye care provider or optometrist/ophthalmologist credentials, date performed, and result.
- Encourage medication adherence.
- Review diabetic services needed at each office visit.
- For members who have not been diagnosed with diabetes but take a diabetes medication for off-label use, document why they are taking medication (for example, weight loss, congestive heart failure, chronic kidney disease, etc.).
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CDCRCM-041661-23-CPN41092 |